Latest news about Gujarat Terce Laboratories
Gujarat Terce Laboratories
35.00
+0.12(+0.34%)
Company Performance:
View Company Insights1D+0.34%
1M-6.94%
6M-21.49%
1Y-32.43%
5Y+291.94%
More news about Gujarat Terce Laboratories
24Feb 26
Gujarat Terce Laboratories Receives Trading Approval for 3,71,000 Equity Shares from Warrant Conversion
Gujarat Terce Laboratories Limited received BSE trading approval for 3,71,000 equity shares of Rs. 10/- face value each, issued at Rs. 27.70/- premium to promoter Aalap Prajapati through warrant conversion. The shares, carrying distinctive numbers 74,20,301 to 77,91,300, commenced trading from February 25, 2026, following BSE approval letter LOD/PREF/SV/394/2025-2026 dated February 24, 2026.
04Feb 26
Gujarat Terce Laboratories Q3FY26 Results: Revenue Declines 3.05% YoY to ₹1,229.35 Lakhs
Gujarat Terce Laboratories reported Q3FY26 revenue of ₹1,229.35 lakhs, down 3.05% from ₹1,268.08 lakhs in Q3FY25, while net profit declined 24.48% to ₹76.11 lakhs from ₹100.80 lakhs year-on-year. Nine-month revenue fell 4.75% to ₹3,607.34 lakhs with net profit at ₹211.05 lakhs versus ₹241.26 lakhs in 9MFY25. The pharmaceutical company's Board approved these unaudited standalone results on February 4, 2026.
28Dec 25
Gujarat Terce Laboratories Schedules Board Meeting for February 4, 2026 to Approve Q3FY26 Financial Results
Gujarat Terce Laboratories Limited announced a board meeting on February 4, 2026, to consider and approve unaudited standalone financial results for Q3FY26 and nine months ending December 31, 2025. The company has implemented a trading window closure from January 1-6, 2026, pursuant to its Code of Conduct for Prevention of Insider Trading, with Company Secretary Ashka Solanki digitally signing the official communication to BSE Limited.
17Dec 25
Gujarat Terce Labs Converts Warrants, Files SEBI Acquisition Disclosure
Gujarat Terce Laboratories successfully converted 3,71,000 warrants into equity shares, with Promoter Managing Director Aalap Natubhai Prajapati's shareholding increasing from 13.22% to 17.35%. The company filed comprehensive SEBI disclosures under multiple regulations, demonstrating full regulatory compliance while raising ₹1.40 crores in additional capital.
08Nov 25
Gujarat Terce Laboratories Reports Record EBITDA Despite Revenue Dip in Q2 FY26
Gujarat Terce Laboratories Limited achieved its highest-ever EBITDA of Rs 194.46 lacs in Q2 FY26, up 11.62% year-over-year, despite a 2.82% revenue decline to Rs 1,292.63 lacs. The EBITDA margin expanded to 15.04% from 13.10%. Net profit decreased by 5.30% to Rs 140.36 lacs. The company attributes the revenue reduction to planned scale-down of low-margin factory B2B sales and rationalization of non-profitable operations. Operating without external funding for three quarters, the pharmaceutical firm has a presence in 13 states with 8 leading brands across 134 products.
11Aug 25
Gujarat Terce Laboratories Reports Q1 Loss, Reshuffles Board Committees
Gujarat Terce Laboratories Limited reported a net loss of Rs 4.35 lakhs for Q1, an improvement from Rs 7.76 lakhs loss in the previous year. Revenue decreased to Rs 1,085.36 lakhs from Rs 1,188.88 lakhs. The company reconstituted its Audit, Nomination and Remuneration, and Stakeholders' Relationship Committees. Statutory auditors provided an unmodified opinion on the quarterly results.
26Jul 25
Gujarat Terce Laboratories Reports Net Loss Despite Revenue Growth, Settles Tax Disputes
Gujarat Terce Laboratories Limited reported a 3.93% increase in total revenue to ₹50.20 crore, with sales rising 4.58% to ₹50.20 crore. EBITDA surged 143.12% to ₹3.89 crore, improving the EBITDA margin from 3.31% to 7.75%. However, the company faced a net loss of ₹0.98 crore due to a one-time tax settlement provision of ₹3.42 crore. The company reduced its debt-to-equity ratio from 0.54 to 0.15 and achieved zero borrowing in Q4. Operational improvements included better inventory and receivables management.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,780.10
(-0.47%)
6,596.50
(+0.30%)
4,339.90
(-0.65%)
1,398.70
(+1.71%)
1,084.60
(+0.74%)
1,267.50
(+0.33%)
2,249.80
(-0.50%)
2,353.00
(-0.70%)
1,463.60
(+1.61%)
1,427.20
(+2.36%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
